Briumvi's Strong Sales Growth Expected to Continue Boosting TG Therapeutics' Revenue in Q2

Earnings
โดย Zacks Investment Research·Read original
Summary · why it matters

TG Therapeutics' multiple sclerosis drug Briumvi generated $201.3 million in total sales in the first quarter of 2026, a 68.2% year-over-year increase, with U.S. net product sales of $194.8 million rising 63%. The company expects U.S. net sales of Briumvi to reach $220 million in the second quarter of 2026, driven by sustained demand. Briumvi, an anti-CD20 monoclonal antibody approved for relapsing forms of MS, faces competition from Roche's Ocrevus and Novartis' Kesimpta, both of which also reported sales growth in the last quarter. TG Therapeutics is conducting label expansion studies for Briumvi in other autoimmune diseases, which could broaden its patient reach and support long-term revenue growth. The company's stock has rallied 78.9% year to date, and the Zacks Consensus Estimate for 2026 earnings per share has risen to $1.50 over the past 60 days.

Impact on stocks 3

Biotech & Genomic Medicine± Mixed · 2 stocks
TG Therapeutics Inc
TGTX
▲ PositiveDemandrelevance

Briumvi sales grew 68.2% YoY and Q2 guidance of $220M indicates sustained demand.

Novartis AG
NOVN
▼ NegativeCompetitionrelevance

Briumvi's strong growth and label expansion studies pose competitive threat to Novartis' Kesimpta.

Health Care▼ · 1 stocks
Roche Holding AG
ROP
▼ NegativeCompetitionrelevance

Briumvi's strong growth and label expansion studies pose competitive threat to Roche's Ocrevus.

© 2026 MarketDXNews